TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06097962: First-in-Human Phase I Study of TIGIT-Blocked NK510 Cells in Patients With PD-1 Refractory Advanced NSCLC

Sponsor: Base Therapeutics (Shanghai) Co., Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,144,720

Rescue Site Savings

+$1,422,288

Unlock Full NCT06097962 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06097962 Rescue Dossier →